Media headlines about Oncobiologics (NASDAQ:ONS) have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oncobiologics earned a news impact score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 42.6660517494238 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Oncobiologics (ONS) traded down $0.10 on Thursday, reaching $1.16. The company’s stock had a trading volume of 89,400 shares, compared to its average volume of 58,750. The company has a debt-to-equity ratio of -0.01, a quick ratio of 0.03 and a current ratio of 0.03. Oncobiologics has a one year low of $0.78 and a one year high of $3.95. The firm has a market capitalization of $29.57 and a price-to-earnings ratio of -0.69.
In other news, CEO Pankaj Mohan sold 104,131 shares of Oncobiologics stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $1.15, for a total value of $119,750.65. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Lawrence A. Kenyon sold 26,165 shares of Oncobiologics stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $1.13, for a total value of $29,566.45. The disclosure for this sale can be found here. Over the last three months, insiders sold 169,831 shares of company stock worth $194,145. 33.50% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3125830/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-oncobiologics-ons-stock-price.html.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.